310 related articles for article (PubMed ID: 29406428)
1. Hepatotoxicity During Isoniazid Preventive Therapy and Antiretroviral Therapy in People Living With HIV With Severe Immunosuppression: A Secondary Analysis of a Multi-Country Open-Label Randomized Controlled Clinical Trial.
Ngongondo M; Miyahara S; Hughes MD; Sun X; Bisson GP; Gupta A; Kumwenda J; Lavenberg JA; Torres TS; Nyirenda M; Kidonge KK; Hosseinipour MC;
J Acquir Immune Defic Syndr; 2018 May; 78(1):54-61. PubMed ID: 29406428
[TBL] [Abstract][Full Text] [Related]
2. Isoniazid-associated hepatitis and antiretroviral drugs during tuberculosis prophylaxis in hiv-infected adults in Botswana.
Tedla Z; Nyirenda S; Peeler C; Agizew T; Sibanda T; Motsamai O; Vernon A; Wells CD; Samandari T
Am J Respir Crit Care Med; 2010 Jul; 182(2):278-85. PubMed ID: 20378730
[TBL] [Abstract][Full Text] [Related]
3. A Trial of Early Antiretrovirals and Isoniazid Preventive Therapy in Africa.
; Danel C; Moh R; Gabillard D; Badje A; Le Carrou J; Ouassa T; Ouattara E; Anzian A; Ntakpé JB; Minga A; Kouame GM; Bouhoussou F; Emieme A; Kouamé A; Inwoley A; Toni TD; Ahiboh H; Kabran M; Rabe C; Sidibé B; Nzunetu G; Konan R; Gnokoro J; Gouesse P; Messou E; Dohoun L; Kamagate S; Yao A; Amon S; Kouame AB; Koua A; Kouamé E; Ndri Y; Ba-Gomis O; Daligou M; Ackoundzé S; Hawerlander D; Ani A; Dembélé F; Koné F; Guéhi C; Kanga C; Koule S; Séri J; Oyebi M; Mbakop N; Makaila O; Babatunde C; Babatounde N; Bleoué G; Tchoutedjem M; Kouadio AC; Sena G; Yededji SY; Assi R; Bakayoko A; Mahassadi A; Attia A; Oussou A; Mobio M; Bamba D; Koman M; Horo A; Deschamps N; Chenal H; Sassan-Morokro M; Konate S; Aka K; Aoussi E; Journot V; Nchot C; Karcher S; Chaix ML; Rouzioux C; Sow PS; Perronne C; Girard PM; Menan H; Bissagnene E; Kadio A; Ettiegne-Traore V; Moh-Semdé C; Kouame A; Massumbuko JM; Chêne G; Dosso M; Domoua SK; N'Dri-Yoman T; Salamon R; Eholié SP; Anglaret X
N Engl J Med; 2015 Aug; 373(9):808-22. PubMed ID: 26193126
[TBL] [Abstract][Full Text] [Related]
4. Nevirapine-associated hepatotoxicity was not predicted by CD4 count ≥250 cells/μL among women in Zambia, Thailand and Kenya.
Peters PJ; Stringer J; McConnell MS; Kiarie J; Ratanasuwan W; Intalapaporn P; Potter D; Mutsotso W; Zulu I; Borkowf CB; Bolu O; Brooks JT; Weidle PJ
HIV Med; 2010 Nov; 11(10):650-60. PubMed ID: 20659176
[TBL] [Abstract][Full Text] [Related]
5. Hepatotoxicity in an African antiretroviral therapy cohort: the effect of tuberculosis and hepatitis B.
Hoffmann CJ; Charalambous S; Thio CL; Martin DJ; Pemba L; Fielding KL; Churchyard GJ; Chaisson RE; Grant AD
AIDS; 2007 Jun; 21(10):1301-8. PubMed ID: 17545706
[TBL] [Abstract][Full Text] [Related]
6. Isoniazid-associated hepatitis in adults infected with HIV receiving 36 months of isoniazid prophylaxis in Botswana.
Tedla Z; Nguyen ML; Sibanda T; Nyirenda S; Agizew TB; Girde S; Rose CE; Samandari T
Chest; 2015 May; 147(5):1376-1384. PubMed ID: 25340318
[TBL] [Abstract][Full Text] [Related]
7. Inactive hepatitis B surface antigen carrier state and hepatotoxicity during antituberculosis chemotherapy.
Lee BH; Koh WJ; Choi MS; Suh GY; Chung MP; Kim H; Kwon OJ
Chest; 2005 Apr; 127(4):1304-11. PubMed ID: 15821209
[TBL] [Abstract][Full Text] [Related]
8. Isoniazid preventive therapy plus antiretroviral therapy for the prevention of tuberculosis: a systematic review and meta-analysis of individual participant data.
Ross JM; Badje A; Rangaka MX; Walker AS; Shapiro AE; Thomas KK; Anglaret X; Eholie S; Gabillard D; Boulle A; Maartens G; Wilkinson RJ; Ford N; Golub JE; Williams BG; Barnabas RV
Lancet HIV; 2021 Jan; 8(1):e8-e15. PubMed ID: 33387480
[TBL] [Abstract][Full Text] [Related]
9. Effect of isoniazid preventive therapy on risk of death in west African, HIV-infected adults with high CD4 cell counts: long-term follow-up of the Temprano ANRS 12136 trial.
Badje A; Moh R; Gabillard D; Guéhi C; Kabran M; Ntakpé JB; Carrou JL; Kouame GM; Ouattara E; Messou E; Anzian A; Minga A; Gnokoro J; Gouesse P; Emieme A; Toni TD; Rabe C; Sidibé B; Nzunetu G; Dohoun L; Yao A; Kamagate S; Amon S; Kouame AB; Koua A; Kouamé E; Daligou M; Hawerlander D; Ackoundzé S; Koule S; Séri J; Ani A; Dembélé F; Koné F; Oyebi M; Mbakop N; Makaila O; Babatunde C; Babatunde N; Bleoué G; Tchoutedjem M; Kouadio AC; Sena G; Yededji SY; Karcher S; Rouzioux C; Kouame A; Assi R; Bakayoko A; Domoua SK; Deschamps N; Aka K; N'Dri-Yoman T; Salamon R; Journot V; Ahibo H; Ouassa T; Menan H; Inwoley A; Danel C; Eholié SP; Anglaret X;
Lancet Glob Health; 2017 Nov; 5(11):e1080-e1089. PubMed ID: 29025631
[TBL] [Abstract][Full Text] [Related]
10. Safety of long-term isoniazid preventive therapy in children with HIV: a comparison of two dosing schedules.
le Roux SM; Cotton MF; Myer L; le Roux DM; Schaaf HS; Lombard CJ; Zar HJ
Int J Tuberc Lung Dis; 2013 Jan; 17(1):26-31. PubMed ID: 23146410
[TBL] [Abstract][Full Text] [Related]
11. The impact of antiretroviral therapy and isoniazid preventive therapy on tuberculosis incidence in HIV-infected patients in Rio de Janeiro, Brazil.
Golub JE; Saraceni V; Cavalcante SC; Pacheco AG; Moulton LH; King BS; Efron A; Moore RD; Chaisson RE; Durovni B
AIDS; 2007 Jul; 21(11):1441-8. PubMed ID: 17589190
[TBL] [Abstract][Full Text] [Related]
12. Empirical tuberculosis therapy versus isoniazid in adult outpatients with advanced HIV initiating antiretroviral therapy (REMEMBER): a multicountry open-label randomised controlled trial.
Hosseinipour MC; Bisson GP; Miyahara S; Sun X; Moses A; Riviere C; Kirui FK; Badal-Faesen S; Lagat D; Nyirenda M; Naidoo K; Hakim J; Mugyenyi P; Henostroza G; Leger PD; Lama JR; Mohapi L; Alave J; Mave V; Veloso VG; Pillay S; Kumarasamy N; Bao J; Hogg E; Jones L; Zolopa A; Kumwenda J; Gupta A;
Lancet; 2016 Mar; 387(10024):1198-209. PubMed ID: 27025337
[TBL] [Abstract][Full Text] [Related]
13. Implementation of isoniazid preventive therapy in an HIV clinic in Cambodia: high rates of discontinuation when combined with antiretroviral therapy.
van Griensven J; Choun K; Chim B; Thai S; Lorent N; Lynen L
Trop Med Int Health; 2015 Dec; 20(12):1823-31. PubMed ID: 26426387
[TBL] [Abstract][Full Text] [Related]
14. Hepatotoxicity due to rifampicin, isoniazid and pyrazinamide in patients with tuberculosis: is anti-HCV a risk factor?
Nader LA; de Mattos AA; Picon PD; Bassanesi SL; De Mattos AZ; Pineiro Rodriguez M
Ann Hepatol; 2010; 9(1):70-4. PubMed ID: 20308724
[TBL] [Abstract][Full Text] [Related]
15. Multicenter study of skin rashes and hepatotoxicity in antiretroviral-naïve HIV-positive patients receiving non-nucleoside reverse-transcriptase inhibitor plus nucleoside reverse-transcriptase inhibitors in Taiwan.
Wu PY; Cheng CY; Liu CE; Lee YC; Yang CJ; Tsai MS; Cheng SH; Lin SP; Lin DY; Wang NC; Lee YC; Sun HY; Tang HJ; Hung CC
PLoS One; 2017; 12(2):e0171596. PubMed ID: 28222098
[TBL] [Abstract][Full Text] [Related]
16. HBV, HCV, and HBV/HCV co-infection among HIV-positive patients in Hunan province, China: Regimen selection, hepatotoxicity, and antiretroviral therapy outcome.
Su S; Fairley CK; Sasadeusz J; He J; Wei X; Zeng H; Jing J; Mao L; Chen X; Zhang L
J Med Virol; 2018 Mar; 90(3):518-525. PubMed ID: 29091279
[TBL] [Abstract][Full Text] [Related]
17. The protective effect of isoniazid preventive therapy on tuberculosis incidence among HIV positive patients receiving ART in Ethiopian settings: a meta-analysis.
Geremew D; Endalamaw A; Negash M; Eshetie S; Tessema B
BMC Infect Dis; 2019 May; 19(1):405. PubMed ID: 31077133
[TBL] [Abstract][Full Text] [Related]
18. Completion of isoniazid preventive therapy among human immunodeficiency virus positive adults in urban Malawi.
Thindwa D; MacPherson P; Choko AT; Khundi M; Sambakunsi R; Ngwira LG; Kalua T; Webb EL; Corbett EL
Int J Tuberc Lung Dis; 2018 Mar; 22(3):273-279. PubMed ID: 29471904
[TBL] [Abstract][Full Text] [Related]
19. Beneficial effect of isoniazid preventive therapy and antiretroviral therapy on the incidence of tuberculosis in people living with HIV in Ethiopia.
Yirdaw KD; Jerene D; Gashu Z; Edginton ME; Kumar AM; Letamo Y; Feleke B; Teklu AM; Zewdu S; Weiss B; Ruff A
PLoS One; 2014; 9(8):e104557. PubMed ID: 25105417
[TBL] [Abstract][Full Text] [Related]
20. Effect of isoniazid preventive therapy on tuberculosis incidence and associated risk factors among HIV infected adults in Tanzania: a retrospective cohort study.
Sabasaba A; Mwambi H; Somi G; Ramadhani A; Mahande MJ
BMC Infect Dis; 2019 Jan; 19(1):62. PubMed ID: 30654753
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
